Becton, Dickinson and Company (NYSE:BDX) Shares Sold by UMB Bank n.a.

22 Jan 2025, 14:22 by Kim Johansen · The Markets Daily

UMB Bank n.a. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,444 shares of the medical instruments supplier’s stock after selling 323 shares during the period. UMB Bank n.a.’s holdings in Becton, Dickinson and Company were worth $1,462,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. State Street Corp raised its position in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after buying an additional 106,616 shares in the last quarter. Geode Capital Management LLC raised its holdings in Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Becton, Dickinson and Company by 6.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after purchasing an additional 302,893 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 597 shares of the company’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares in the company, valued at approximately $1,311,211.44. The trade was a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,344 shares of company stock valued at $2,090,716 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BDX has been the topic of a number of research analyst reports. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Get Our Latest Research Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $240.19 on Wednesday. The company has a 50-day moving average of $227.13 and a two-hundred day moving average of $232.70. The stock has a market cap of $69.66 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $248.42.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company posted $3.42 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.73%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.